Karyopharm Therapeutics Inc (KPTI)
1.095
0.00 (0.00%)
USD |
NASDAQ |
Apr 24, 16:00
1.095
0.00 (0.00%)
After-Hours: 19:54
Karyopharm Therapeutics Revenue (Quarterly): 33.75M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 33.75M |
| September 30, 2023 | 36.01M |
| June 30, 2023 | 37.58M |
| March 31, 2023 | 38.70M |
| December 31, 2022 | 33.58M |
| September 30, 2022 | 36.14M |
| June 30, 2022 | 39.68M |
| March 31, 2022 | 47.67M |
| December 31, 2021 | 126.27M |
| September 30, 2021 | 37.69M |
| June 30, 2021 | 22.60M |
| March 31, 2021 | 23.26M |
| December 31, 2020 | 35.10M |
| September 30, 2020 | 21.33M |
| June 30, 2020 | 33.51M |
| March 31, 2020 | 18.14M |
| December 31, 2019 | 18.10M |
| September 30, 2019 | 13.15M |
| June 30, 2019 | 9.493M |
| March 31, 2019 | 0.155M |
| December 31, 2018 | 0.206M |
| September 30, 2018 | 0.239M |
| June 30, 2018 | 19.89M |
| Date | Value |
|---|---|
| March 31, 2018 | 10.00M |
| December 31, 2017 | 1.534M |
| September 30, 2017 | |
| June 30, 2017 | 0.003M |
| March 31, 2017 | 0.068M |
| December 31, 2016 | 0.047M |
| September 30, 2016 | 0.048M |
| June 30, 2016 | 0.059M |
| March 31, 2016 | |
| December 31, 2015 | 0.025M |
| September 30, 2015 | 0.075M |
| June 30, 2015 | 0.15M |
| March 31, 2015 | |
| December 31, 2014 | 0.015M |
| September 30, 2014 | 0.021M |
| June 30, 2014 | 0.021M |
| March 31, 2014 | 0.171M |
| December 31, 2013 | 0.021M |
| September 30, 2013 | |
| June 30, 2013 | 0.133M |
| March 31, 2013 | 0.233M |
| December 31, 2012 | 0.033M |
| September 30, 2012 | 0.034M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
9.493M
Minimum
Jun 2019
126.27M
Maximum
Dec 2021
34.83M
Average
33.75M
Median
Dec 2023
Revenue (Quarterly) Benchmarks
| Geron Corp | 0.023M |
| Arbutus Biopharma Corp | 2.145M |
| Verastem Inc | -- |
| Actinium Pharmaceuticals Inc | 0.081M |
| Chimerix Inc | 0.004M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -41.84M |
| Total Expenses (Quarterly) | 71.56M |
| EPS Diluted (Quarterly) | -0.36 |
| Enterprise Value | 104.90M |
| Gross Profit Margin (Quarterly) | 95.60% |
| Profit Margin (Quarterly) | -124.0% |
| Earnings Yield | -114.2% |
| Normalized Earnings Yield | -113.99 |